Notice of Appeal

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

NICE has received 1 appeal, that falls within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisation:

• Eisai Europe Limited

The appeal panel will convene on Tuesday 21 October 2025 at 10:00am via Zoom to hear oral representations from the appellant.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

Where possible, requests to attend should be made using the registration link that will be available on our website from 14 August 2024. The registration period for this appeal will end at 4:00pm on Tuesday 14 October 2025.

Further details relating to public attendance at this appeal are available on the same webpage as above.